Numerous studies have reported that levels of AD-relevant biomarkers such as phosphorylated-tau at threonine 181 (p-tau181) [2], Aβ1–40 [3], and Aβ1–42 [3] in cerebrospinal fluid (CSF) and plasma are associated with AD diagnosis. The gene discussed is MAPT; the disease is Alzheimer disease.